Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Yaw Adu, Saurav Das, Dhaani Ailawadhi, Andre Fernandez, Ricardo Parrondo, Vivek Roy, Taimur Sher, Sean O'Connell, Ahsan Rasheed, Asher A Chanan- Khan, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 2418.

https://doi.org/10.1182/blood-2023-189642

Published: 2023

Journal Articles

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Ashley Zimmerman, Keisha Heslop, Dustin Chapin, Taimur Sher, Vivek Roy, Ahsan Rasheed, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9331–9332.

https://doi.org/10.1182/blood-2022-165377

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Sikander Ailawadhi, Ricardo D Parrondo, Betsy Laplant, Victoria R. Alegria, Jamie B Elliott, Taimur Sher, Aneel Paulus, Dustin Chapin, Keisha Heslop, Asher Chanan-Khan, Vivek Roy

Blood (2022) 140 (Supplement 1): 4450–4451.

https://doi.org/10.1182/blood-2022-164656

Published: 2022

Journal Articles

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Sikander Ailawadhi, Ricardo D Parrondo, Aneel Paulus, Betsy Laplant, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Taimur Sher, Vivek Roy, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 9904–9905.

https://doi.org/10.1182/blood-2022-164667

Published: 2022

Journal Articles

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Sikander Ailawadhi, Ricardo D Parrondo, Gabriela Perez, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Ernesto Ayala, Patrick J O'Brien, Vivek Roy, Victoria R. Alegria, Ashley Zimmerman, Dustin Chapin, Stephanie Lanier, Carly Kasik, Schannon Bradley, Taimur Sher, Aneel Paulus, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 10165–10166.

https://doi.org/10.1182/blood-2022-165209

Published: 2022

Journal Articles

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Sikander Ailawadhi, Jay R. Hydren, Leyla Bojanini, Nathan W. Sweeney, Felicia Seng, Mizba Baksh, Ahsan Rasheed, Mays Abdulazeez, Meghna Ailawadhi, Keren George, Ricardo D Parrondo, Vivek Roy, Victoria R. Alegria, Pooja Advani, Rami Manochakian, Jason S. Starr, Taimur Sher, Jennifer M. Ahlstrom, Asher Chanan-Khan

Blood (2022) 140 (Supplement 1): 7941–7942.

https://doi.org/10.1182/blood-2022-167005

Published: 2022

Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood (2022) 140 (Supplement 1): 10017–10019.

https://doi.org/10.1182/blood-2022-167181

Published: 2022

Journal Articles

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Ricardo D Parrondo, Lindsay Brooke Gardner, Mohamad Alhaj Moustafa, Vivek Roy, Taimur Sher, Ahsan Rasheed, Rahma M Warsame, Jeremy T. Larsen, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Rafael Fonseca, Asher Chanan-Khan, Sikander Ailawadhi

Blood (2022) 140 (Supplement 1): 7237–7238.

https://doi.org/10.1182/blood-2022-169533

Published: 2022

Journal Articles

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Blood (2022) 140 (18): 1997–2000.

https://doi.org/10.1182/blood.2022017616

Published: 2022

Includes: Supplemental data

Journal Articles

Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM)

Ricardo D Parrondo, Zaid Abdel Rahman, Michael G. Heckman, Mikolaj Wieczorek, Liuyan Jiang, Hassan B. Alkhateeb, Mark R. Litzow, Patricia Greipp, Taimur Sher, Leif Bergsagel, Rafael Fonseca, Vivek Roy, Angela Dispenzieri, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Sikander Ailawadhi, James M. Foran

Blood (2021) 138 (Supplement 1): 2285.

https://doi.org/10.1182/blood-2021-151574

Published: 2021

Journal Articles

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Blood (2021) 138 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2021-147925

Published: 2021

Journal Articles

Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience

Farah Yassine, Mohamed A. Kharfan-Dabaja, Athanasios Tsalatsanis, Vivek Roy, Abba C. Zubair, Hemant S. Murthy, Ernesto Ayala, Madiha Iqbal, Taimur Sher, Sikander Ailawadhi, Ricardo D Parrondo

Blood (2021) 138 (Supplement 1): 665.

https://doi.org/10.1182/blood-2021-152635

Published: 2021

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory)

Blood (2021) 138 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2021-151668

Published: 2021

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Journal Articles

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Leyla Bojanini Molina, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140390

Published: 2020

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

NARROW

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM)

"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience

Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory)

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only